These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 3382232)
1. [Evaluation of BRM in skin cancer]. Ishihara K Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1603-8. PubMed ID: 3382232 [TBL] [Abstract][Full Text] [Related]
2. [Clinical efficacy of intratumoral administration of BRM in advanced cancer and their mechanism of actions]. Kuninobu H; Toge T; Takayama T; Baba N; Kegoya Y; Yanagawa E Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2769-73. PubMed ID: 2782888 [TBL] [Abstract][Full Text] [Related]
3. [On the behalf of the Japanese Society of Biological Response Modifiers]. Ishihara K Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):906-11. PubMed ID: 2730029 [TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of BRMs in gastric cancer patients]. Ochiai T; Isono K Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1609-14. PubMed ID: 2968070 [TBL] [Abstract][Full Text] [Related]
13. Biological Response Modifiers Programme and cancer chemotherapy. Oldham RK Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts. Feng N; Jin H; Wang M; Du C; Wright JA; Young AH Cancer Chemother Pharmacol; 2003 Mar; 51(3):247-55. PubMed ID: 12655444 [TBL] [Abstract][Full Text] [Related]